Saturday, July 11, 2026

biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM

AXIM Biotechnologies

AXIM Biotechnologies is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker AXIM. Primary therapeutic focus areas include Neuroblastoma, Hyperinflammation, Sepsis, craniopharyngioma, Del

18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM · NYSE Ticker
Company details
Status
Public
HQ
18 East 50th Street, 5 Floor, New York, NY 10022, US
Founded
2011
Employees
7
Programs
20
Drugs
52
Patents
138
Clinical program

Chewing Gum

Phase 1 · small molecule · THC

Chewing Gum for THC is a Phase 1 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).

← All AXIM BIOTECHNOLOGIES, INC. projects Phase 1 small molecule active

Internal code MedChew

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AXIM BIOTECHNOLOGIES, INC.
Phase
Phase 1
Modality
small_molecule
Indication
THC
Status
active
Trials
1